Trial Outcomes & Findings for B40 Non-Invasive Blood Pressure Equivalency Study (NCT NCT01546285)

NCT ID: NCT01546285

Last Updated: 2013-06-21

Results Overview

The primary endpoints are the difference in systolic, diastolic and mean blood pressure values between the B40 Monitor and PRO1000. The mean of the difference should be no more than 5mmHg and the standard deviation of the difference should be no more than 8mmHg per the AAMI SP-10 standard.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

66 participants

Primary outcome timeframe

End of each blood pressure reading

Results posted on

2013-06-21

Participant Flow

Healthy subjects were recruited from 03.07.2012 - 03.23.2012 from Clinimark LLC, an independent physiology lab.

Subject distribution requirements (i.e. gender, blood pressure, and arm circumference)were reviewed as part of screening prior to subject enrollment.

Participant milestones

Participant milestones
Measure
Blood Pressure Reading
Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
Overall Study
STARTED
66
Overall Study
COMPLETED
66
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

B40 Non-Invasive Blood Pressure Equivalency Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Blood Pressure Reading
n=66 Participants
Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
Age, Categorical
<=18 years
17 Participants
n=39 Participants
Age, Categorical
Between 18 and 65 years
45 Participants
n=39 Participants
Age, Categorical
>=65 years
4 Participants
n=39 Participants
Age Continuous
32 years
STANDARD_DEVIATION 19.7 • n=39 Participants
Sex: Female, Male
Female
38 Participants
n=39 Participants
Sex: Female, Male
Male
28 Participants
n=39 Participants
Region of Enrollment
United States
66 participants
n=39 Participants
Systolic Blood Pressure
125.0 mmHg
STANDARD_DEVIATION 25.3 • n=39 Participants
Diastolic Blood Pressure
73 mmHg
STANDARD_DEVIATION 15.4 • n=39 Participants
Mean Arterial Pressure (MAP)
92.7 mmHg
STANDARD_DEVIATION 17.2 • n=39 Participants

PRIMARY outcome

Timeframe: End of each blood pressure reading

Population: 66 subjects were enrolled. 64 subjects contributed data to the study. Subject 058 had a lateral difference of the reference diastolic blood pressure more than 10mmHg, and NIBP data was excluded from final analysis as specified in AAMI SP-10 standard. And Subject 046 had circulation issues and no data was collected.

The primary endpoints are the difference in systolic, diastolic and mean blood pressure values between the B40 Monitor and PRO1000. The mean of the difference should be no more than 5mmHg and the standard deviation of the difference should be no more than 8mmHg per the AAMI SP-10 standard.

Outcome measures

Outcome measures
Measure
B40 and PRO1000 - Systolic BP
n=64 Participants
Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
B40 and PRO1000 - Diastolic BP
n=64 Participants
B40 and PRO1000 - MAP
n=64 Participants
Difference Between the B40 Monitor and Reference Device DINAMAP PRO1000 on NIBP Measurements
-1.4 mmHg
Standard Deviation 4.8
-3.3 mmHg
Standard Deviation 2.6
-3.7 mmHg
Standard Deviation 4.2

Adverse Events

Blood Pressure Reading

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jeffrey Conner - Global Research Manager

GE Healthcare

Phone: 414.721.2423

Results disclosure agreements

  • Principal investigator is a sponsor employee The sponsor cannot require changes to the PI's disclosure, with the exception of requesting the removal of sponsor's confidential information. The study results themselves are not considered confidential information. Sponsor cannot extend the embargo beyond 60 days unless the PI's disclosure contains patentable subject matter, in which an embargo beyond 60 days may be necessary to allow for the filing of a patent application
  • Publication restrictions are in place

Restriction type: OTHER